| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 1997;96:3248-3250.)
© 1997 American Heart Association, Inc.
Articles |
Obesity and Heart Disease
A Statement for Healthcare Professionals From the Nutrition Committee, American Heart Association
Key Words: AHA Medical/Scientific Statements • obesity • cardiovascular diseases • coronary disease • heart failure
 |
Introduction |
|---|
 Top Introduction Definition of ObesityObesity and Coronary Heart...Congestive Heart FailureTreatment of Obesity and...References |
|---|
Obesity is an increasingly prevalent metabolic disorder affecting not only the US population but also that of the developing world. It is estimated from the third National Health and Nutrition Examination Survey (NHANES III) (1988-1991) that 33% of the US population is obese, compared with 25% in NHANES II (1976-1980).1 Fatness is associated with a number of comorbidities, including several forms of heart disease. Although heredity explains 30% to 70% of cases of obesity, environmental contributions to the increasing prevalence of obesity must be sought since the gene pool has remained stable over the same interval. Diets high in fat (and calories)2 and a reduced expenditure of energy in the form of physical activity3 are the most likely explanations. However, in the United States, despite the reduction in consumption of fat from approximately 40% of calories in 1965 to 34% of calories in 1991,4 a decrease in incidence of obesity has not occurred. This is likely attributable to both maintenance of fat intake with an increase in total caloric intake and reduced physical activity. Interestingly, in developing countries some comorbidities are seen at a lesser degree of excess weight, suggesting that relative weight may be as important as absolute adiposity.
|
Definition of Obesity |
|---|
|
TopIntroductionDefinition of ObesityObesity and Coronary Heart...Congestive Heart FailureTreatment of Obesity and...References |
|---|
The definition of obesity, or being overweight,5 remains controversial. In the United States, mortality data provided by the Metropolitan Life Insurance Company historically have been used to define obesity.6 Yet these data relate to mortality only, and the definition depends on a person's frame (size), which is arbitrary and not independently related to obesity-related mortality or comorbidities. Body mass index (BMI) has recently gained favor as a better measure of adiposity.7 8 BMI is defined as weight in kilograms divided by height in meters squared (kg/m2). A threshold level of BMI to define obesity is not entirely appropriate because in women, a BMI <21 may be associated with the greatest protection from coronary heart disease mortality.9 Yet for many women a BMI near 30 may still not be of concern when the increase in adipose tissue is distributed in the pelvis and not the abdomen. Substantial evidence now indicates that an increased waist circumference, or waist-to-hip ratio, predicts comorbidities and mortality from obesity.10 11 Unfortunately, a BMI-based definition fails to take body fat distribution into account.
|
Obesity and Coronary Heart Disease |
|---|
|
TopIntroductionDefinition of ObesityObesity and Coronary Heart...Congestive Heart FailureTreatment of Obesity and...References |
|---|
Until recently the relation between obesity and coronary heart disease was viewed as indirect, ie, through covariates related to both obesity and coronary heart disease risk,12 including hypertension; dyslipidemia, particularly reductions in HDL cholesterol; and impaired glucose tolerance or non–insulin-dependent diabetes mellitus. Insulin resistance and accompanying hyperinsulinemia are typically associated with these comorbidities.13 Although most of the comorbidities relating obesity to coronary artery disease increase as BMI increases, they also relate to body fat distribution. Long-term longitudinal studies, however, indicate that obesity as such not only relates to but independently predicts coronary atherosclerosis.9 14 15 This relation appears to exist for both men and women with minimal increases in BMI. In a 14-year prospective study, middle-aged women with a BMI >23 but <25 had a 50% increase in risk of nonfatal or fatal coronary heart disease,9 and men aged 40 to 65 years with a BMI >25 but <29 had a 72% increased risk.16 The overall relation between obesity and coronary artery disease morbidity and mortality is less clear for Hispanics,17 Pima Indians,18 and African-American women.19
|
Congestive Heart Failure |
|---|
|
TopIntroductionDefinition of ObesityObesity and Coronary Heart...Congestive Heart FailureTreatment of Obesity and...References |
|---|
Left ventricular hypertrophy is common in patients with obesity and to some extent is related to systemic hypertension.20 However, abnormalities in left ventricular mass and function also occur in the absence of hypertension21 and may be related to the severity of obesity.22 Hypertension is approximately three times more common in obese than normal-weight persons.23 This relationship may be cause-and-effect in that when weight increases, so does blood pressure,24 whereas when weight decreases, blood pressure falls.25
Increased left ventricular volume and wall stress in addition to increased stroke volume and cardiac output are commonly seen in systemic hypertension.21 26 The hypertrophy of the left ventricle is both concentric and eccentric, and diastolic dysfunction is common. When obesity is present but systemic hypertension is absent, left ventricular volume is often increased, but wall stress usually remains normal. However, in obese patients without hypertension, increases in stroke volume and cardiac output as well as diastolic dysfunction are seen. These changes in the left ventricle are related to sudden death in obese patients. When 22 patients with severe obesity were examined postmortem, dilated cardiomyopathy was most frequently associated with sudden death (n=10), with severe coronary atherosclerosis (n=6), concentric left ventricular hypertrophy without dilatation (n=4), pulmonary embolism (n=1), and hypoplastic coronary arteries (n=1) also found.22 Thus, dilated cardiomyopathies, presumably with concomitant cardiac arrhythmias, may be the most common cause of sudden death in patients with severe obesity. The prolonged QT interval also seen in obesity27 may predispose to such arrhythmias.
Changes in the right heart also occur in obesity. The pathophysiology is related to obstructive sleep apnea and/or the obesity hypoventilation syndrome, which produce pulmonary hypertension and right ventricular hypertrophy, dilatation, progressive dysfunction, and finally failure.28 29 However, right ventricular dysfunction can also occur as a consequence of left ventricular dysfunction, and the heart failure that develops is often biventricular.21
|
Treatment of Obesity and Heart Disease |
|---|
|
TopIntroductionDefinition of ObesityObesity and Coronary Heart...Congestive Heart FailureTreatment of Obesity and...References |
|---|
In patients with congestive heart failure, sodium restriction and small reductions in weight may dramatically improve ventricular function and oxygenation.30 31 In addition, several studies suggest that the more extensive weight reduction that follows gastrointestinal surgery for obesity reduces cardiovascular mortality32 and in persons with non–insulin-dependent diabetes, both cardiovascular and total mortality.33 Moreover, although many studies have demonstrated the beneficial effects of weight reduction on cardiovascular risk factors such as hypertension25 34 35 and dyslipidemia,36 37 recent studies from Sweden indicate that the major reduction of body weight that follows gastrointestinal surgery for obesity also reduces incidence of non–insulin-dependent diabetes mellitus.38 Shortening of the QT interval also follows weight reduction.39 Thus, weight reduction appears efficacious in reducing risks of coronary heart disease and congestive heart failure and potentially preventing heart disease in obese patients.
Treatment of obesity should be based on its severity and the presence
of comorbidities, eg, congestive heart failure,
dyslipidemia, hypertension, non–insulin dependent
diabetes, and obstructive sleep apnea. Maintaining a BMI <25
throughout adult life has been recently recommended.40 For
most patients with a BMI between 25 and 30, lifestyle modifications
including diet and exercise are appropriate. Diets should be modestly
restricted in calories; evidence suggests that obese patients who have
slower rates of weight reduction have the same long-term outcomes as
patients undergoing more rapid weight reduction.41
Restricting consumption of fat to <30% of total calories should also
be prescribed because low-fat diets may also promote weight
reduction.42 When rapid weight loss is needed, eg, for
severe biventricular heart failure, more severe caloric
restriction, eg, 
800 calories daily, with at least 0.75 g/kg
bioavailable protein, can be used.43 For less-urgent
weight reduction, a loss of 0.45 kg (1 lb) per week is
reasonable.44 This rate of weight loss would require a
caloric deficit of about 400 calories per day.
Training programs that increase physical activity have had a variable effect on body mass and composition.45 46 However, simply changing daily routines, eg, parking farther away and using the stairs rather than the elevator, may also be effective.47 Once weight loss has been achieved, a more vigorous exercise program may also enhance maintenance of reduction in weight.48
Pharmaceuticals should be considered with a BMI >30 or with less-severe obesity and comorbidities.49 50 The rationale for use and discussion with the patient about adverse effects of the medications should be documented in the patient's record. If the risk from obesity is sufficiently serious to indicate use of antiobesity drugs, long-term use should be anticipated. However, a case-control study in Europe demonstrated that patients treated with dexfenfluramine for more than 3 months had an odds ratio of 23.1 (95% confidence interval, 6.9 to 77.7) of developing primary pulmonary hypertension.51 A potential link between fenfluramine therapy of obese patients with valvular heart disease has also been raised.52 As a result, both fenfluramine and dexfenfluramine have been withdrawn from the market. Few drug choices remain. Like other nonsurgical therapies for obesity, once antiobesity drugs are discontinued, weight gain typically follows.53
When the BMI is >35 and comorbidities exist, gastrointestinal surgery becomes a consideration. When the BMI is >40, surgery is the treatment of choice. The experience of the surgeon and type of operation chosen predict outcome. In general, a Roux-en-Y gastric bypass is superior to gastric plication.54
Although weight reduction is not recommended for patients with a BMI <25, some patients in this category clearly have risks related to body fat distribution. Although measurement of waist circumference may help identify such patients, this assessment is crude, and other approaches are more expensive, ie, magnetic resonance imaging and computed tomography. Moreover, the radiation risk with some techniques (eg, computed tomography) precludes their use in children.
No matter what the therapeutic approach, it is important to realize that obesity is a disorder and recidivism is common, with <5% of patients maintaining their reduced weight at 4 years.55 Thus, therapeutic regimens must be maintained indefinitely; even then, only surgery has been proved to produce substantial sustained long-term weight loss. Prevention of obesity by diet and regular physical activity remains the highest priority for maintaining cardiovascular health. This is particularly important for small children and adolescents.
|
Footnotes |
|---|
"Obesity and Heart Disease" was approved by the American Heart Association Science Advisory and Coordinating Committee in August 1997.
A single reprint is available by calling 800-242-8721 (US only) or writing the American Heart Association, Public Information, 7272 Greenville Avenue, Dallas, TX 75231-4596. Ask for reprint No. 71-0130.
|
References |
|---|
|
TopIntroductionDefinition of ObesityObesity and Coronary Heart...Congestive Heart FailureTreatment of Obesity and...References |
|---|
1. Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among U.S. adults: the National Health and Nutrition Examination Survey. JAMA. 1994;272:205-211.
2. Lissner L, Heitmann BL. Dietary fat and obesity: evidence from epidemiology. Eur J Clin Nutr. 1995;49:79-90.[Medline] [Order article via Infotrieve]
3. Williamson DF, Madans J, Anda RF, Kleinman JC, Kahn HS, Byers T. Recreational physical activity and ten-year weight change in a US national cohort. Int J Obes. 1993;17:279-286.[Medline] [Order article via Infotrieve]
4.
Popkin BM, Siega-Riz AM, Haines PS. A
comparison of dietary trends among racial and socioeconomic groups in
the United States. N Engl J Med. 1996;335:716-720.
5.
Abernathy RP, Black DR. Healthy body weights:
an alternative approach. Am J Clin Nutr. 1996;63:448S-451S.
6. Metropolitan Life Insurance Company. Metropolitan height and weight tables. Stat Bull Met Life Ins Co. 1983;64:2.
7. Kraemer H, Berkowitz RI, Hammer LD. Methodological difficulties in studies of obesity, I: measurement issues. Ann Behav Med. 1990;12:112-118.
8.
Must A, Dallal GE, Dietz WH. Reference data for
obesity: 85th and 95th percentiles of body mass index
(wt/ht2) and triceps skinfold thickness.
Am J Clin Nutr. 1991;53:839-846.
9.
Manson JE, Willett WC, Stampfer MJ, Colditz GA, Hunter
DJ, Hankinson SE, Hennekens CH, Speizer FE. Body weight and
mortality among women. N Engl J Med. 1995;333:677-685.
10. Lapidus L, Bengtsson C, Larsson B, Pennert K, Rybo E, Sjostrom L. Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the population study of women in Gothenburg, Sweden. BMJ. 1984;289:1257-1261.
11. Larsson B, Svardsudd K, Welin L, Wilhelmsen L, Bjorntorp P, Tibblin G. Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913. BMJ. 1984;288:1401-1404.
12. Lew EA, Garfinkel L. Variations in mortality by weight among 750,000 men and women. J Chronic Dis. 1979;32:563-576.[Medline] [Order article via Infotrieve]
13. Reaven GM. Banting lecture: role of insulin resistance in human disease. Diabetes. 1988;37:1595-1607.[Abstract]
14. Garrison RJ, Castelli WP. Weight and thirty-year mortality of men in the Framingham Study. Ann Intern Med. 1985;103:1006-1009.
15. Rabkin SW, Mathewson FA, Hsu PH. Relation of body weight to development of ischemic heart disease in a cohort of young North American men after a 26 year observation period: the Manitoba Study. Am J Cardiol. 1977;39:452-458.[Medline] [Order article via Infotrieve]
16.
Rimm EB, Stampfer MJ, Giovannucci E, Ascherio A,
Spiegelman D, Colditz GA, Willett WC. Body size and fat
distribution as predictors of coronary heart disease among
middle-aged and older US men. Am J Epidemiol. 1995;141:1117-1127.
17. Stern MP, Patterson JK, Mitchell BD, Haffner SM, Hazuda HP. Overweight and mortality in Mexican Americans. Int J Obes. 1990;14:623-629.[Medline] [Order article via Infotrieve]
18.
Pettitt DJ, Lisse JR, Knowler WC, Bennett PH.
Mortality as a function of obesity and diabetes mellitus.
Am J Epidemiol. 1982;115:359.
19.
Stevens J, Keil JE, Rust PF, Tyroler HA, Davis CE,
Gazes PC. Body mass index and body girths as predictors of
mortality in black and white women. Arch Intern Med. 1992;152:1257-1262.
20. Messerli FH. Cardiovascular effects of obesity and hypertension. Lancet. 1982;1:1165-1168.[Medline] [Order article via Infotrieve]
21. Alpert MA, Hashimi MW. Obesity and the heart. Am J Med Sci. 1993;306:117-123.[Medline] [Order article via Infotrieve]
22. Duflou J, Virmani R, Rabin I, Burke A, Farb A, Smialek J. Sudden death as a result of heart disease in morbid obesity. Am Heart J. 1995;130:306-313.[Medline] [Order article via Infotrieve]
23. Van Itallie TB. Health implications of overweight and obesity in the United States. Ann Intern Med. 1985;103:983-988.
24. Kannel WB, Brand N, Skinner JJ Jr, Dawber TR, McNamara PM. The relation of adiposity to blood pressure and development of hypertension: the Framingham study. Ann Intern Med. 1967;67:48-59.
25. Reisin E, Frohlich ED, Messerli FH, Dreslinski GR, Dunn FG, Jones MM, Batson HM Jr. Cardiovascular changes after weight reduction in obesity hypertension. Ann Intern Med. 1983;98:315-319.
26.
Messerli FH, Aepfelbacher FC. Hypertension and
left ventricular hypertrophy.
Hypertension. 1995;13:549-557.
27. Frank S, Colliver JA, Frank A. The electrocardiogram in obesity: statistical analysis of 1,029 patients. J Am Coll Cardiol. 1986;7:295-299.[Abstract]
28. Burwell CS, Robin ED, Whaley RD, Bickelmann AG. Extreme obesity associated with alveolar hypoventilation. Am J Med. 1956;21:811.[Medline] [Order article via Infotrieve]
29. Menashe VD, Farrehi C, Miller M. Hypoventilation and cor pulmonale due to chronic upper airway obstruction. J Pediatr. 1965;67:198-203.
30. Alexander JK. The cardiomyopathy of obesity. Prog Cardiovasc Dis. 1985;27:325-333.[Medline] [Order article via Infotrieve]
31. Estes EH Jr, Seider HO, McIntosh HD. Reversible cardiopulmonary syndrome with extreme obesity. Circulation. 1957;16:179-187.[Medline] [Order article via Infotrieve]
32. Matts JP, Buchwald H, Fitch LL, Campos CT, Varco RL, Campbell GS, Pearce MB, Yellin AE, Smink RD Jr, Sawin HS Jr, Long JM. Subgroup analyses of the major clinical endpoints in the program on the surgical control of the hyperlipidemias (Posch): overall mortality, atherosclerotic coronary heart disease (ACHD) mortality, and ACHD mortality or myocardial infarction. J Clin Epidemiol. 1995;48:389-405.[Medline] [Order article via Infotrieve]
33. McDonald KG, Long SD, Swanson MS, Brown BM, Morris P, Dohm GL, Pories WJ. The gastric bypass operation reduces the progression and mortality of non-insulin dependent diabetes mellitus. J Gastrointestinal Surg. 1997. In press.
34.
Scherrer U, Nussberger J, Torriani S, Waeber B, Dariolo
R, Hofstetter JR, Brunner HR. Effect of weight reduction in
moderately overweight patients on recorded ambulatory blood
pressure and free cytosolic platelet calcium.
Circulation. 1991;83:552-558.
35. De Simone G, Mancini M, Mainenti G, Turco S, Ferrara LA. Weight reduction lowers blood pressure independently of salt restriction. J Endocrinol Invest. 1992;15:339-343.[Medline] [Order article via Infotrieve]
36. Rossner S, Bjorvell H. Early and late effects of weight loss on lipoprotein metabolism in severe obesity. Atherosclerosis. 1987;64:125-130.[Medline] [Order article via Infotrieve]
37.
Zimmerman J, Kaufmann NA, Fainaru M, Eisenberg S,
Oschry Y, Friedlander Y, Stein Y. Effect of weight loss on
moderate obesity on plasma lipoprotein and apolipoprotein levels and on
high density lipoprotein composition.
Arteriosclerosis. 1984;4:115-123.
38. Sjöström L. Obesity and weight change in relation to disease. Obes Res. 1996;4(suppl 1):3S.
39. Carella MJ, Mantz SL, Rovner DR, Willis PW III, Gossain VV, Bouknight RR, Ferenchick GS. Obesity, adiposity, and lengthening of the QT interval: improvement after weight loss. Int J Obes. 1996;20:938-942.
40.
Meisler JG, St. Jeor S. Summary and
recommendations from the American Health Foundation's Expert Panel on
Healthy Weight. Am J Clin Nutr. 1996;63:474S-477S.
41. Wadden TA, Goster GS, Letizia KA. One-year behavioral treatment of obesity: comparison of moderate and severe caloric restriction and the effects of weight maintenance therapy. J Consult Clin Psychol. 1994;62:165-171.[Medline] [Order article via Infotrieve]
42.
Schaefer EJ, Lichtenstein AH, Lamon-Fava S, McNamara
JR, Schaefer MM, Rasmussen H, Ordovas JM. Body weight and
low-density lipoprotein cholesterol changes after
consumption of a low-fat ad libitum diet. JAMA. 1995;274:1450-1455.
43.
Fisler JS. Cardiac effects of starvation and
semistarvation diets: safety and mechanisms of action.
Am J Clin Nutr. 1992;56:230S–234S.
44. Subcommittee of Nutritionists for the American Heart Association Nutrition Committee. American Heart Association guidelines for weight management programs for healthy adults. Heart Dis Stroke. 1994;3:221-228.[Medline] [Order article via Infotrieve]
45. Hadjiolova I, Mintcheva L, Dunev S, Daleva M, Handjiev S, Balabanski L. Physical working capacity in obese women after an exercise programme for body weight reduction. Int J Obes. 1982;6:405-410.[Medline] [Order article via Infotrieve]
46. Hagen RD, Upton SJ, Wong L, Whittam J. The effects of aerobic conditioning and/or caloric restriction in overweight men and women. Med Sci Sports Exerc. 1986;18:87-94.[Medline] [Order article via Infotrieve]
47. Epstein LH, Valoski AM, Kalarchian MA, McCurley J. Do children lose and maintain weight easier than adults: a comparison of child and parent weight changes from six months to ten years. Obes Res. 1995;3:411-417.[Medline] [Order article via Infotrieve]
48. Ewbank PP, Darga LL, Lucas CP. Physical activity as a predictor of weight maintenance in previously obese subjects. Obes Res. 1995;3:257-263.[Medline] [Order article via Infotrieve]
49.
National Task Force on the Prevention and Treatment of
Obesity. Long-term pharmacotherapy in the management of obesity.
JAMA. 1996;276:1907-1915.
50. Pi-Sunyer X. Guidelines for the approval and use of obesity drugs. Obes Res. 1995;3:473-478.[Medline] [Order article via Infotrieve]
51.
Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J,
Kurz X, Higenbottam T, Oakley C, Wouters E, Aubier M, Simonneau G,
Begaud B. Appetite-suppressant drugs and the risk of primary
pulmonary hypertension. N Engl J
Med. 1996;335:609-616.
52.
Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards
BS, Edwards WD, Schaff HV. Valvular heart disease
associated with commonly prescribed diet pills. N
Engl J Med. 1997;337:581-588.
53. Weintraub M. Long-term weight control study. Clin Pharmacol Ther. 1992;51:581-643.[Medline] [Order article via Infotrieve]
54. Consensus statement: NIH Consensus Development Conference. Gastrointestinal surgery for severe obesity. Am J Clin Nutr. 1992;55:615-619.
55. Kramer FM, Jeffery RW, Forster JL. Long-term follow-up of behavioral treatment for obesity: patterns of weight regain among men and women. Int J Obes. 1989;13:123-136.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  M. E. Waring, M. B. Roberts, D. R. Parker, and C. B. Eaton Documentation and Management of Overweight and Obesity in Primary Care J Am Board Fam Med, September 1, 2009; 22(5): 544 - 552. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C J D'HELFT, P C BRENNAN, A M MCGEE, S L MCFADDEN, C M HUGHES, J R WINDER, and L A RAINFORD Potential Irish dose reference levels for cardiac interventional examinations Br. J. Radiol., April 1, 2009; 82(976): 296 - 302. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. C. Bruce, Y. Guo, K. C. Lawson, A. K. Manatunga, S. F. Auyeung, W. M. McDonald, N. Rushing, A. R. Brown, N. Gilles, M. Emery, et al. Platelet Thromboxane A2 Secretion in Patients With Major Depression Responsive to Electroconvulsive Therapy Psychosom Med, April 1, 2008; 70(3): 319 - 327. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. K. Surmi, R. D. Atkinson, M. L. Gruen, K. R. Coenen, and A. H. Hasty The role of macrophage leptin receptor in aortic root lesion formation Am J Physiol Endocrinol Metab, March 1, 2008; 294(3): E488 - E495. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W.-J. Zhang, K. E. Bird, T. S. McMillen, R. C. LeBoeuf, T. M. Hagen, and B. Frei Dietary {alpha}-Lipoic Acid Supplementation Inhibits Atherosclerotic Lesion Development in Apolipoprotein E Deficient and Apolipoprotein E/Low-Density Lipoprotein Receptor Deficient Mice Circulation, January 22, 2008; 117(3): 421 - 428. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Zhu, W. Yan, D. Ge, F. A. Treiber, G. A. Harshfield, G. Kapuku, H. Snieder, and Y. Dong Relationships of Cardiovascular Phenotypes With Healthy Weight, at Risk of Overweight, and Overweight in US Youths Pediatrics, January 1, 2008; 121(1): 115 - 122. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. S. Vlachos, A. Hatziioannou, A. Perelas, and D. N. Perrea Sonographic Assessment of Regional Adiposity Am. J. Roentgenol., December 1, 2007; 189(6): 1545 - 1553. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Evans, M. Collins, C. Jennings, L. van der Merwe, I. Soderstrom, T. Olsson, N. S Levitt, E. V Lambert, and J. H Goedecke The association of interleukin-18 genotype and serum levels with metabolic risk factors for cardiovascular disease Eur. J. Endocrinol., November 1, 2007; 157(5): 633 - 640. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. R. Coenen and A. H. Hasty Obesity potentiates development of fatty liver and insulin resistance, but not atherosclerosis, in high-fat diet-fed agouti LDLR-deficient mice Am J Physiol Endocrinol Metab, August 1, 2007; 293(2): E492 - E499. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. de Simone, R. B. Devereux, M. Chinali, L. G. Best, E. T. Lee, J. M. Galloway, H. E. Resnick, and for the Strong Heart Study Investigators Prognostic Impact of Metabolic Syndrome by Different Definitions in a Population With High Prevalence of Obesity and Diabetes: The Strong Heart Study Diabetes Care, July 1, 2007; 30(7): 1851 - 1856. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. L. Haheim, S. Tonstad, I. Hjermann, P. Leren, and I. Holme Predictiveness of body mass index for fatal coronary heart disease in men according to length of follow-up: A 21-year prospective cohort study Scand J Public Health, January 1, 2007; 35(1): 4 - 10. [Abstract] [PDF]
|
|
|
|
 |
|
 P. Poirier, T. D. Giles, G. A. Bray, Y. Hong, J. S. Stern, F. X. Pi-Sunyer, and R. H. Eckel Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Arterioscler Thromb Vasc Biol, May 1, 2006; 26(5): 968 - 976. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Poirier, T. D. Giles, G. A. Bray, Y. Hong, J. S. Stern, F. X. Pi-Sunyer, and R. H. Eckel Obesity and Cardiovascular Disease: Pathophysiology, Evaluation, and Effect of Weight Loss: An Update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease From the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism Circulation, February 14, 2006; 113(6): 898 - 918. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Lopez-Jimenez, S. Bhatia, M. L. Collazo-Clavell, M. G. Sarr, and V. K. Somers Safety and Efficacy of Bariatric Surgery in Patients With Coronary Artery Disease Mayo Clin. Proc., September 1, 2005; 80(9): 1157 - 1162. [Abstract] [PDF]
|
|
|
|
 |
|
 J. H.K. Vogel, S. F. Bolling, R. B. Costello, E. M. Guarneri, M. W. Krucoff, J. C. Longhurst, B. Olshansky, K. R. Pelletier, C. M. Tracy, R. A. Vogel, et al. Integrating Complementary Medicine Into Cardiovascular Medicine: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents (Writing Committee to Develop an Expert Consensus Document on Complementary and Integrative Medicine) J. Am. Coll. Cardiol., July 5, 2005; 46(1): 184 - 221. [Full Text] [PDF]
|
|
|
|
 |
|
 D. C. W. Lau, B. Dhillon, H. Yan, P. E. Szmitko, and S. Verma Adipokines: molecular links between obesity and atheroslcerosis Am J Physiol Heart Circ Physiol, May 1, 2005; 288(5): H2031 - H2041. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. D. Christou, C. L. Gentile, C. A. DeSouza, D. R. Seals, and P. E. Gates Fatness Is a Better Predictor of Cardiovascular Disease Risk Factor Profile Than Aerobic Fitness in Healthy Men Circulation, April 19, 2005; 111(15): 1904 - 1914. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M.A. Kennedy, K. Dickstein, S. D. Anker, K. Kristianson, R. Willenheimer, and OPTIMAAL Study Group The prognostic importance of body mass index after complicated myocardial infarction J. Am. Coll. Cardiol., January 4, 2005; 45(1): 156 - 158. [Full Text] [PDF]
|
|
|
|
 |
|
 K. L. Kind, C. T. Roberts, A. I. Sohlstrom, A. Katsman, P. M. Clifton, J. S. Robinson, and J. A. Owens Chronic maternal feed restriction impairs growth but increases adiposity of the fetal guinea pig Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2005; 288(1): R119 - R126. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Neville, C. V. R. Brown, J. Weng, D. Demetriades, and G. C. Velmahos Obesity Is an Independent Risk Factor of Mortality in Severely Injured Blunt Trauma Patients Arch Surg, September 1, 2004; 139(9): 983 - 987. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Eyre, R. Kahn, R. M. Robertson, and and the ACS/ADA/AHA Collaborative Writing Committe Preventing Cancer, Cardiovascular Disease, and Diabetes: A Common Agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association Stroke, August 1, 2004; 35(8): 1999 - 2010. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Eyre, R. Kahn, R. M. Robertson, and the ACS/ADA/AHA Collaborative Writing Committe, N. G. Clark, C. Doyle, T. Gansler, T. Glynn, Y. Hong, R. A. Smith, et al. Preventing Cancer, Cardiovascular Disease, and Diabetes: A Common Agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association CA Cancer J Clin, July 1, 2004; 54(4): 190 - 207. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Eyre, R. Kahn, and R. M. Robertson Preventing Cancer, Cardiovascular Disease, and Diabetes: A common agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association Diabetes Care, July 1, 2004; 27(7): 1812 - 1824. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. E. Alvarez, T. P. Ballard, S. D. Beske, and K. P. Davy Subcutaneous obesity is not associated with sympathetic neural activation Am J Physiol Heart Circ Physiol, July 1, 2004; 287(1): H414 - H418. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Eyre, R. Kahn, R. M. Robertson, the ACS/ADA/AHA Collaborative Writing Committee, ACS/ADA/AHA Collaborative Writing Committee Member, N. G. Clark, C. Doyle, Y. Hong, T. Gansler, T. Glynn, et al. Preventing Cancer, Cardiovascular Disease, and Diabetes: A Common Agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association Circulation, June 29, 2004; 109(25): 3244 - 3255. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. L. Horvath, S. Diano, and M. Tschop Brain Circuits Regulating Energy Homeostasis Neuroscientist, June 1, 2004; 10(3): 235 - 246. [Abstract] [PDF]
|
|
|
|
|
|
K. P. Davy and J. E. Hall Obesity and hypertension: two epidemics or one? Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2004; 286(5): R803 - R813. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. L. Cheal, F. Abbasi, C. Lamendola, T. McLaughlin, G. M. Reaven, and E. S. Ford Relationship to Insulin Resistance of the Adult Treatment Panel III Diagnostic Criteria for Identification of the Metabolic Syndrome Diabetes, May 1, 2004; 53(5): 1195 - 1200. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Lopez-Jimenez, S. J. Jacobsen, G. S. Reeder, S. A. Weston, R. A. Meverden, and V. L. Roger Prevalence and Secular Trends of Excess Body Weight and Impact on Outcomes After Myocardial Infarction in the Community Chest, April 1, 2004; 125(4): 1205 - 1212. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Karason, L. Sjostrom, I. Wallentin, and M. Peltonen Impact of blood pressure and insulin on the relationship between body fat and left ventricular structure Eur. Heart J., August 2, 2003; 24(16): 1500 - 1505. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I Campbell The obesity epidemic: can we turn the tide? Heart, May 1, 2003; 89(90002): ii22 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Douglas, G. L. Bakris, M. Epstein, K. C. Ferdinand, C. Ferrario, J. M. Flack, K. A. Jamerson, W. E. Jones, J. Haywood, R. Maxey, et al. Management of High Blood Pressure in African Americans: Consensus Statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks Arch Intern Med, March 10, 2003; 163(5): 525 - 541. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Yologlu, A. T. Sezgin, R. Ozdemir, N. Sezgin, C. Colak, E. Topal, and I. Barutcu Identifying Risk Factors in a Mostly Overweight Patient Population with Coronary Artery Disease Angiology, March 1, 2003; 54(2): 181 - 186. [Abstract] [PDF]
|
|
|
|
|
|
References Circulation, December 17, 2002; 106(25): 3373 - 3421. [Full Text]
|
|
|
|
|
|
G. E. Alvarez, S. D. Beske, T. P. Ballard, and K. P. Davy Sympathetic Neural Activation in Visceral Obesity Circulation, November 12, 2002; 106(20): 2533 - 2536. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Pearson, S. N. Blair, S. R. Daniels, R. H. Eckel, J. M. Fair, S. P. Fortmann, B. A. Franklin, L. B. Goldstein, P. Greenland, S. M. Grundy, et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases Circulation, July 16, 2002; 106(3): 388 - 391. [Full Text] [PDF]
|
|
|
|
 |
|
 M. GLICK Screening for traditional risk factors for cardiovascular disease: A review for oral health care providers J Am Dent Assoc, March 1, 2002; 133(3): 291 - 300. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Gruberg, N. J. Weissman, R. Waksman, S. Fuchs, R. Deible, E. E. Pinnow, L. M. Ahmed, K. M. Kent, A. D. Pichard, W. O. Suddath, et al. The impact of obesity on the short-term andlong-term outcomes after percutaneous coronary intervention: the obesity paradox? J. Am. Coll. Cardiol., February 20, 2002; 39(4): 578 - 584. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Beske, G. E. Alvarez, T. P. Ballard, and K. P. Davy Reduced cardiovagal baroreflex gain in visceral obesity: implications for the metabolic syndrome Am J Physiol Heart Circ Physiol, February 1, 2002; 282(2): H630 - H635. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. B. Horwich, G. C. Fonarow, M. A. Hamilton, W. R. MacLellan, M. A. Woo, and J. H. Tillisch The relationship between obesity and mortality in patients with heart failure J. Am. Coll. Cardiol., September 1, 2001; 38(3): 789 - 795. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Al Suwaidi, S. T. Higano, D. R. Holmes Jr., R. Lennon, and A. Lerman Obesity is independently associated with coronary endothelial dysfunction in patients with normal or mildly diseased coronary arteries J. Am. Coll. Cardiol., May 1, 2001; 37(6): 1523 - 1528. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Holvoet, A. Mertens, P. Verhamme, K. Bogaerts, G. Beyens, R. Verhaeghe, D. Collen, E. Muls, and F. Van de Werf Circulating Oxidized LDL Is a Useful Marker for Identifying Patients With Coronary Artery Disease Arterioscler Thromb Vasc Biol, May 1, 2001; 21(5): 844 - 848. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. C. Gallagher, O. Geling, J. FitzGibbons, J. Aforismo, and F. Comite Are Women Being Counseled about Estrogen Replacement Therapy? Med Care Res Rev, November 1, 2000; 57(3_suppl): 72 - 92. [Abstract] [PDF]
|
|
|
|
|
|
G. J. Balady, P. A. Ades, P. Comoss, M. Limacher, I. L. Pina, D. Southard, M. A. Williams, and T. Bazzarre Core Components of Cardiac Rehabilitation/Secondary Prevention Programs : A Statement for Healthcare Professionals From the American Heart Association and the American Association of Cardiovascular and Pulmonary Rehabilitation Writing Group Circulation, August 29, 2000; 102(9): 1069 - 1073. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Sundquist and M. Winkleby Country of birth, acculturation status and abdominal obesity in a national sample of Mexican-American women and men Int. J. Epidemiol., June 1, 2000; 29(3): 470 - 477. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
National Task Force on the Prevention and Treatmen Overweight, Obesity, and Health Risk Arch Intern Med, April 10, 2000; 160(7): 898 - 904. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Instructions for Authors Nutr Clin Pract, February 1, 2000; 15(1): 2 - 2. [PDF]
|
|
|
|
|
|
C. M. Apovian Invited Review: The Medical Management of Obesity and the Role of Pharmacotherapy: An Update Nutr Clin Pract, February 1, 2000; 15(1): 5 - 12. [Abstract] [PDF]
|
|
|
|
|
|
S. M. Grundy, T. Bazzarre, J. Cleeman, R. B. D’Agostino Sr, M. Hill, N. Houston-Miller, W. B. Kannel, R. Krauss, H. M. Krumholz, R. M. Lauer, et al. Prevention Conference V : Beyond Secondary Prevention : Identifying the High-Risk Patient for Primary Prevention : Medical Office Assessment : Writing Group I Circulation, January 4, 2000; 101 (1): e3 - e11. [Full Text] [PDF]
|
|
|
|
|
|
C. Hofman-Bang, J. Lisspers, R. Nordlander, A. Nygren, O. Sundin, A. Ohman, and L. Ryden Two-year results of a controlled study of residential rehabilitation for patients treated with percutaneous transluminal coronary angioplasty. A randomized study of a multifactorial programme Eur. Heart J., October 2, 1999; 20(20): 1465 - 1474. [Abstract] [PDF]
|
|
|
|
|
|
S. M. Grundy, R. Pasternak, P. Greenland, S. Smith Jr, and V. Fuster Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology J. Am. Coll. Cardiol., October 1, 1999; 34(4): 1348 - 1359. [Full Text] [PDF]
|
|
|
|
|
|
S. M. Grundy, R. Pasternak, P. Greenland, S. Smith Jr, and V. Fuster Assessment of Cardiovascular Risk by Use of Multiple-Risk-Factor Assessment Equations : A Statement for Healthcare Professionals From the American Heart Association and the American College of Cardiology Circulation, September 28, 1999; 100(13): 1481 - 1492. [Full Text] [PDF]
|
|
|
|
|
|
S. M. Grundy Primary Prevention of Coronary Heart Disease : Integrating Risk Assessment With Intervention Circulation, August 31, 1999; 100(9): 988 - 998. [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Davidson, J. Hauptman, M. DiGirolamo, J. P. Foreyt, C. H. Halsted, D. Heber, D. C. Heimburger, C. P. Lucas, D. C. Robbins, J. Chung, et al. Weight Control and Risk Factor Reduction in Obese Subjects Treated for 2 Years With Orlistat: A Randomized Controlled Trial JAMA, January 20, 1999; 281(3): 235 - 242. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Field, R. M. Krauss, R. H. Eckel, W. H. Dietz, A. L. Franks, J. S. Marks, G. A. Gaesser, J. M. McGinnis, W. H. Foege, A. Werner, et al. The Obesity Problem N. Engl. J. Med., April 16, 1998; 338(16): 1156 - 1158. [Full Text]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||